|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
LHGDN |
These results suggest that rs1617640 in the EPO promoter is significantly associated with PDR and ESRD.
|
18458324 |
2008 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the light of the enthusiasm regarding the use of recombinant human erythropoietin (Epo) and its analogues for treatment of the anaemias of chronic renal failure and malignancies it is worth remembering that today's success has been based on a century of laborious research.
|
17253966 |
2007 |
|
Kidney Failure, Chronic
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats.
|
16707910 |
2006 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human erythropoietin gene therapy for patients with chronic renal failure.
|
15798000 |
2005 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the erythropoiesis in chronic renal failure could be attributed to the influence of QA on EPO synthesis.
|
12620922 |
2003 |
|
Kidney Failure, Chronic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Purified 1 x 10(4) circulating CD34+ cells isolated from rHuEPO-hyporesponsive HD patients (EPO-H; n = 10), rHuEPO-responsive non-HD patients with CRF (EPO-R; n = 8), nonanemic HD patients without rHuEPO therapy (EPO-W/O; n = 10), and healthy volunteer controls (CON; n = 10) were subjected to a methylcellulose culture system supplemented with rHuEPO, recombinant human interleukin-3 (IL-3), recombinant human stem cell factor (SCF), and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for 14 days.
|
12612986 |
2003 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the efficacy of EPO gene therapy using adenovirus vector for chronic renal failure mice expressing severe renal anemia.
|
10200985 |
1999 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated anemia.
|
10326023 |
1998 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients.
|
8903857 |
1996 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anemia is an invariable consequence of end-stage renal failure (ESRF) and recombinant erythropoietin has dramatically improved the quality of life of patients with ESRF.
|
7706487 |
1995 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The peripheral red cell count is kept constant by a closely controlled feedback mechanism involving O2 supply, erythropoietin secretion and erythropoiesis; the system may become unbalanced in conditions such as chronic renal disease, chronic inflammation and prematurity.
|
7658325 |
1995 |
|
Kidney Failure, Chronic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human erythropoietin represents a major breakthrough in the treatment of patients with chronic renal failure.
|
1992884 |
1991 |